The FTSE 100 advanced 0.3% to close at 9,720.51, with heavyweight resource names providing much of the upward momentum. The mid-cap FTSE 250 also added just over 0.3% to 22,165.17,
The FTSE 100 advanced 0.3% to close at 9,720.51, with heavyweight resource names providing much of the upward momentum. The mid-cap FTSE 250 also added just over 0.3% to 22,165.17,
Rachel Reeves will announce a three-year stamp duty holiday for newly listed companies in her Budget, in a bid to reignite London’s struggling stock market and lure more firms to
City of London Traders Lament ‘Fate Worse Than Death’ as Screens Go Dark
The Death Cross There are of course many financial news and information services. Too many. There are the boring, yet snooty macro ones, like Bloomberg or CNBC, that obsess about
Elon Musk has reportedly indicated that X, previously known as Twitter, might become unavailable in Europe to bypass new EU regulations.
Twitter Inc (NYSE: TWTR) has warned that it might instigate legal proceedings against its competitor, Meta Platforms Inc (NASDAQ: FB), due to the striking similarities between their new app, Threads,
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
Activation of First Clinical Trial Site in the U.S
While it may have initially been modelled as a microblogging platform, Twitter has, over time, become a place for traders to look out for trends in the stock market and
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board